Comparative Pharmacology
Head-to-head clinical analysis: ANGIOMAX versus DICUMAROL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ANGIOMAX versus DICUMAROL.
ANGIOMAX vs DICUMAROL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Direct thrombin inhibitor that reversibly binds to the active site of thrombin, blocking its interaction with substrates, thereby inhibiting fibrin formation and activation of coagulation factors V, VIII, and XIII.
Dicumarol is a vitamin K antagonist that inhibits the synthesis of vitamin K-dependent clotting factors (II, VII, IX, X) and anticoagulant proteins C and S by blocking the reduction of vitamin K epoxide to vitamin K hydroquinone in the liver.
1 mg/kg intravenous bolus followed by 0.1 mg/kg/hour continuous intravenous infusion for duration of procedure; alternatively, 0.75 mg/kg intravenous bolus followed by 1.75 mg/kg/hour continuous intravenous infusion for up to 4 hours during percutaneous coronary intervention.
Initial oral dose 200-300 mg once daily for 2-3 days, then maintenance 25-200 mg once daily adjusted to target INR of 2.0-3.0 for most indications. Administered orally.
None Documented
None Documented
Terminal elimination half-life: 25-30 minutes in patients with normal renal function; increased to 2-3 hours in dialysis-dependent patients
24–48 hours; prolonged in hepatic impairment or with CYP2C9 polymorphisms.
Renal: ~90% unchanged; biliary/fecal: negligible (<1%)
Primarily renal as inactive metabolites; minimal biliary/fecal. ~95% renal, ~5% fecal.
Category C
Category C
Anticoagulant
Anticoagulant